Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

PHASE3CompletedINTERVENTIONAL
Enrollment

589

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Actinic Keratosis
Interventions
DRUG

Imiquimod Cream, 3.75%

DRUG

Zyclara®

OTHER

Vehicle of Test Product

Trial Locations (23)

19034

Philadelphia Institute of Dermatology, Fort Washington

30263

MedaPhase, Inc., Newnan

32073

Park Avenue Dermatology, PA, Orange Park

32174

Leavitt Medical Associates of Florida dba Ameriderm Research, Ormond Beach

32216

Jacksonville Center for Clinical Research, Jacksonville

33144

International Dermatology Research, Inc., Miami

33162

Tory Sullivan, M.D., P.A., North Miami Beach

33472

Visions Clinical Research, Boynton Beach

33761

Tampa Bay Medical Research, Clearwater

33781

Radiant Research, Inc., Pinellas Park

40202

Dermatology Specialists Research LLC, Louisville

45249

Radiant Research, Inc., Cincinnati

46168

The Indiana Clinical Trials Center, Plainfield

60005

Altman Dermatology Associates, Arlington Heights

75234

Research Across America, Dallas

80501

Longmont Clinic, PC, Longmont

85710

Radiant Research, Inc., Tucson

90045

Dermatology Research Associates, Los Angeles

91436

Encino Research Center, Encino

92117

Skin Surgery Medical Group, Inc., San Diego

95821

Northern California Research, Sacramento

97223

Oregon Medical Research Center, PC, Portland

02886

Omega Medical Research, Warwick

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT01686152 - Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis | Biotech Hunter | Biotech Hunter